Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Cash & Equivalents (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Cash & Equivalents for 7 consecutive years, with $48.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents changed N/A to $48.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $48.0 million for FY2025, N/A changed from the prior year.
  • Cash & Equivalents for Q4 2025 was $48.0 million at Actinium Pharmaceuticals, down from $53.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $116.3 million in Q2 2022, with the low at $48.0 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $81.3 million, with a median of $81.9 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents soared 42.02% in 2022, then crashed 32.12% in 2025.
  • Over 5 years, Cash & Equivalents stood at $77.8 million in 2021, then surged by 39.93% to $108.9 million in 2022, then dropped by 29.6% to $76.7 million in 2023, then increased by 2.59% to $78.7 million in 2024, then plummeted by 38.98% to $48.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $48.0 million, $53.4 million, and $59.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.